Data with Sanofi’s investigational enzyme replacement therapy avalglucosidase alfa in late-onset Pompe disease and infantile-onset Pompe disease will be featured as platform and poster presentations at the 17th annual WORLDSymposiumTM, to be held February 8-12, 2021.

In a groundbreaking study, scientists at Harvard University identified an enzyme that seems to dictate the limits of human physical performance.

Jacobus Pharmaceutical Co. Inc. won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.